- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02633514
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Kailiang Wu, MD.PhD.
- Phone Number: 86722 +86 64175590
- Email: wukailiang@aliyun.com
Study Contact Backup
- Name: Xingwen Fan, MD
- Phone Number: +8613651669687
- Email: wenxingfan@126.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 20032
- Recruiting
- Kailiang Wu
-
Contact:
- Kailiang Wu, M.D. Ph. D.
- Phone Number: 86722 +86 64175590
- Email: wukailiang@aliyun.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
18~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed ; incomplete resection (R1 or R2);have adequate bone marrow, hepatic, and renal function;Patients receive incomplete resection within 3 months; Written informed consent.
Exclusion Criteria:
Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Radiochemotherapy
adjuvant radiochemotherapy after incomplete resection: Cisplatin + Etoposide + Radiotherapy (60Gy / 30FX)
|
25mg/m2,iv gtt,d1-3
Other Names:
75mg/m2,iv gtt,d1-3
Other Names:
60Gy/30Fx
|
Sham Comparator: radiotherapy
adjuvant radiotherapy after incomplete resection: Radiotherapy (60Gy / 30FX)
|
60Gy/30Fx
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: 2 years
|
from registration to disease progression or death.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 2 years
|
from registration to death as a result of any cause
|
2 years
|
Number of Participants with Treatment- Related Adverse Events as Assessed by CTCAE v4.0
Time Frame: 2 years
|
Assessed by CTCAE v4.0
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kailiang Wu, MD. PhD, Fudan University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Lymphatic Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Thoracic Neoplasms
- Neoplasms, Complex and Mixed
- Carcinoma
- Thymoma
- Thymus Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Etoposide
Other Study ID Numbers
- 1508151-6
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thymoma and Thymic Carcinoma
-
National Cancer Institute (NCI)TerminatedInvasive Thymoma and Thymic Carcinoma | Recurrent Thymoma and Thymic Carcinoma | Stage III Thymoma | Stage IVA Thymoma | Stage IVB ThymomaUnited States
-
Erasmus Medical CenterHospices Civils de Lyon; Maastro Clinic, The NetherlandsRecruitingThymic Carcinoma | Thymoma | Thymic Epithelial Tumor | Thymoma and Thymic CarcinomaNetherlands
-
MedSIRMerck Sharp & Dohme LLCActive, not recruitingMetastatic Thymic Carcinoma | Thymoma Type B3Spain, France, Italy
-
Jian ChenRecruitingCarbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, ChemotherapyChina
-
Sun Yat-sen UniversityActive, not recruitingThymoma and Thymic CarcinomaChina
-
Fudan UniversityCompletedThymoma and Thymic CarcinomaChina
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingUnresectable Thymic Carcinoma | Metastatic Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Recurrent Thymic CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Thymoma AJCC v8 | Stage IIIA Thymoma AJCC v8 | Stage IIIB Thymoma AJCC v8 | Stage IV Thymoma AJCC v8 | Stage IVA Thymoma AJCC v8 | Stage IVB Thymoma AJCC v8 | Unresectable Thymic CarcinomaUnited States
-
Tang-Du HospitalRecruitingThymoma and Thymic CarcinomaChina
-
Armando Santoro, MDCompletedThymoma and Thymic CarcinomaItaly
Clinical Trials on Cisplatin
-
Insmed IncorporatedCompletedOsteosarcoma MetastaticUnited States
-
West China Second University HospitalRecruitingNeoadjuvant Chemotherapy | Epithelial Carcinoma, OvarianChina
-
Privo TechnologiesNational Cancer Institute (NCI)CompletedOral Squamous Cell CarcinomaUnited States
-
Samsung Medical CenterUnknownNasophayngeal Carcinoma Between Stage II and IVbKorea, Republic of
-
Cedars-Sinai Medical CenterRecruitingHPV Positive Oropharyngeal Squamous Cell CarcinomaUnited States
-
Korea Cancer Center HospitalCompletedCervical CancersKorea, Republic of
-
Taiho Oncology, Inc.Quintiles, Inc.Completed
-
Sun Yat-sen UniversityActive, not recruitingNasopharyngeal CarcinomaChina
-
Lawson Health Research InstituteRecruitingLocally Advanced Head and Neck Squamous Cell CarcinomaCanada
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaboratorsActive, not recruitingNasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck NeoplasmChina